In vivo characterization of MMP-2200, a mixed δ/μ opioid agonist, in mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 336, Issue 3, 2011, Pages 767-778

  Lowery, John J ^a   Raymond, Tyler J ^a   Giuvelis, Denise ^a   Bidlack, Jean M ^b   Polt, Robin ^c   Bilsky, Edward J ^a  

^a UNIVERSITY OF NEW ENGLAND   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

^c University of Arizona   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA FUNALTREXAMINE; DELTA OPIATE RECEPTOR AGONIST; METHYL IODIDE; MMP 2200; MORPHINE; MU OPIATE RECEPTOR AGONIST; NALOXONE; NALTRINDOLE; NORBINALTORPHIMINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; BREATHING; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG TOLERANCE; GASTROINTESTINAL TRANSIT; IN VIVO STUDY; LOCOMOTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TAIL FLICK TEST; WITHDRAWAL SYNDROME;

ANALGESICS, OPIOID; ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; GLYCOPEPTIDES; HUMANS; MALE; MICE; MICE, INBRED ICR; MOTOR ACTIVITY; PAIN MEASUREMENT; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, MU;

EID: 79951964544     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.172866     Document Type: Article

References (40)

1. Bilsky EJ, Egleton RD, Mitchell SA, Palian MM, Davis P, Huber JD, Jones H, Yamamura HI, Janders J, Davis TP, et al. (2000) Enkephalin glycopeptide analogues produce analgesia with reduced dependence liability. J Med Chem 43: 2586-2590. (Pubitemid 30437141)
2. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
3. Brainin-Mattos J, Smith ND, Malkmus S, Rew Y, Goodman M, Taulane J, and Yaksh TL (2006) Cancer-related bone pain is attenuated by a systemically available delta-opioid receptor agonist. Pain 122:174-181.
4. Brennan F, Carr DB, and Cousins M (2007) Pain management: a fundamental human right. Anesth Analg 105:205-221. (Pubitemid 46975867)
5. Burgoyne DS (2007) Prevalence and economic implications of chronic pain. Manag Care 16(Suppl 3):2-4.
6. Cahill CM, Holdridge SV, and Morinville A (2007) Trafficking of delta-opioid receptors and other G-protein-coupled receptors: implications for pain and analgesia. Trends Pharmacol Sci 28:23-31. (Pubitemid 46049831)
7. Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 percent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
8. Codd EE, Carson JR, Colburn RW, Stone DJ, Van Besien CR, Zhang SP, Wade PR, Gallantine EL, Meert TF, Molino L, et al. (2009) JNJ-20788560 [9-(8-azabicyclo[3.2.1]oct-3-ylidene)-9H-xanthene-3-carboxylic acid diethylamide], a selective delta opioid receptor agonist, is a potent and efficacious antihyperalgesic agent that does not produce respiratory depression, pharmacologic tolerance, or physical dependence. J Pharmacol Exp Ther 329:241-251.
9. Cowan A, Zhu XZ, Mosberg HI, Omnaas JR, and Porreca F (1988) Direct dependence studies in rats with agents selective for different types of opioid receptor. J Pharmacol Exp Ther 246:950-955.
10. Dhanasekaran M and Polt R (2005) New prospects for glycopeptide based analgesia: glycoside-induced penetration of the blood-brain barrier. Curr Drug Deliv 2:59-73. (Pubitemid 40590922)
11. Do Carmo GP, Polt R, Bilsky EJ, Rice KC, and Negus SS (2008) Behavioral pharmacology of the mu/delta opioid glycopeptide MMP2200 in rhesus monkeys. J Pharmacol Exp Ther 326:939-948.
12. Dondio G, Ronzoni S, Farina C, Graziani D, Parini C, Petrillo P, and Giardina GA (2001) Selective delta opioid receptor agonists for inflammatory and neuropathic pain. Farmaco 56:117-119. (Pubitemid 32372595)
13. Egleton R, Bilsky E, Tollin G, Dhanasekaran M, Lowery J, Alves I, Davis P, Porreca F, Yamamura H, Yeomans L, et al. (2005) Biousian glycopeptides penetrate the blood-brain barrier. Tetrahedron Asymmetry 16:65-75. (Pubitemid 40127076)
14. Elmagbari NO, Egleton RD, Palian MM, Lowery JJ, Schmid WR, Davis P, Navratilova E, Dhanasekaran M, Keyari CM, Yamamura HI, et al. (2004) Antinociceptive structure-activity studies with enkephalin-based opioid glycopeptides. J Pharmacol Exp Ther 311:290-297. (Pubitemid 39287808)
15. Fields HL, Emson PC, Leigh BK, Gilbert RF, and Iversen LL (1980) Multiple opiate receptor sites on primary afferent fibres. Nature 284:351-353. (Pubitemid 10122188)
16. Gomes I, Gupta A, Filipovska J, Szeto HH, Pintar JE, and Devi LA (2004) A role for heterodimerization of mu and delta opiate receptors in enhancing morphine analgesia. Proc Natl Acad Sci USA 101:5135-5139. (Pubitemid 38469214)
17. Gray AC, Coupar IM, and White PJ (2006) Comparison of opioid receptor distributions in the rat central nervous system. Life Sci 79:674-685. (Pubitemid 43949408)
18. Gutstein H and Akil H (2005) Opioid analgesics, in Goodman & Gilman's The Pharmacological Basis of Therapeutics (Brunton L, Lazo J, and Parker K eds) pp 547-590, McGraw-Hill, New York.
19. Heyman JS, Koslo RJ, Mosberg HI, Tallarida RJ, and Porreca F (1986) Estimation of the affinity of naloxone at supraspinal and spinal opioid receptors in vivo: studies with receptor selective agonists. Life Sci 39:1795-1803. (Pubitemid 16006171)
20. Holdridge SV and Cahill CM (2007) Spinal administration of a delta opioid receptor agonist attenuates hyperalgesia and allodynia in a rat model of neuropathic pain. Eur J Pain 11:685-693. (Pubitemid 46830764)
21. Horan P, Taylor J, Yamamura HI, and Porreca F (1992) Extremely long-lasting antagonistic actions of nor-binaltorphimine (nor-BNI) in the mouse tail-flick test. J Pharmacol Exp Ther 260:1237-1243.
22. Hylden JL and Wilcox GL (1980) Intrathecal morphine in mice: a new technique. Eur J Pharmacol 67:313-316. (Pubitemid 10007057)
23. Jannsen P, Niemegeers C, and Dorg J (1963) The inhibitory effects of fentanyl and other morphine-like analgesics on the warm water-induced tail withdrawal reflex in rats. Arzneim-Forch Drug Res 13:502-507.
24. Jiang Q, Heyman JS, and Porreca F (1989) Mu antagonist and kappa agonist properties of β-funaltrexamine (β-FNA): long lasting spinal antinociception. NIDA Res Monogr 95:199-205. (Pubitemid 20347186)
25. Lowery JJ, Yeomans L, Keyari CM, Davis P, Porreca F, Knapp BI, Bidlack JM, Bilsky EJ, and Polt R (2007) Glycosylation improves the central effects of DAMGO. Chem Biol Drug Des 69:41-47. (Pubitemid 46277779)
26. McNicol E, Horowicz-Mehler N, Fisk RA, Bennett K, Gialeli-Goudas M, Chew PW, Lau J, Carr D, and American Pain Society (2003) Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. J Pain 4:231-256. (Pubitemid 36807905)
27. Pattinson KT (2008) Opioids and the control of respiration. Brit J Anaesth 100:747-758.
28. Petrillo P, Angelici O, Bingham S, Ficalora G, Garnier M, Zaratin PF, Petrone G, Pozzi O, Sbacchi M, Stean TO, et al. (2003) Evidence for a selective role of the δ-opioid agonist [8R-(4bS*,8aβ,8aβ,12bβ)] 7,10-Dimethyl-1-methoxy-11-(2-methylpropyl) oxycarbonyl 5,6,7,8,12,12b- hexahydro-(9H)-4,8-methanobenzofuro[ 3,2-e]pyrrolo[2,3-g]isoquinoline hydrochloride (SB-235863) in blocking hyperalgesia associated with inflammatory and neuropathic pain responses. J Pharmacol Exp Ther 307:1079-1089. (Pubitemid 37498200)
29. Polt R, Dhanasekaran M, and Keyari CM (2005) Glycosylated neuropeptides: a new vista for neuropsychopharmacology? Med Res Rev 25:557-585. (Pubitemid 41233371)
30. Porreca F, Mosberg HI, Hurst R, Hruby VJ, and Burks TF (1984) Roles of mu, delta, and kappa opioid receptors in spinal and supraspinal mediation of gastrointestinal transit effects and hot-plate analgesia in the mouse. J Pharmacol Exp Ther 230:341-348. (Pubitemid 14061610)
31. Raehal KM, Lowery JJ, Bhamidipati CM, Paolino RM, Blair JR, Wang D, Sadée W, and Bilsky EJ (2005) In vivo characterization of 6β-naltrexol, an opioid ligand with less inverse agonist activity compared with naltrexone and naloxone in opioiddependent mice. J Pharmacol Exp Ther 313:1150-1162. (Pubitemid 40727018)
32. Rozenfeld R, Abul-Husn NS, Gomez I, and Devi LA (2007) An emerging role for the delta opioid receptor in the regulation of mu opioid receptor function. Sci World J 7:64-73. (Pubitemid 350292609)
33. Scherrer G, Tryoen-Tóth P, Filliol D, Matifas A, Laustriat D, Cao YQ, Basbaum AI, Dierich A, Vonesh JL, Gavériaux-Ruff C, et al. (2006) Knockin mice expressing fluorescent delta-opioid receptors uncover G protein-coupled receptor dynamics in vivo. Proc Natl Acad Sci USA 103:9691-9696. (Pubitemid 43955886)
34. Schiller PW (2010) Bi- or multifunctional opioid peptide drugs. Life Sci 86:598-603.
35. Sheldon RJ, Qi JA, Porreca F, and Fisher LA (1990) Gastrointestinal motor effects of corticotrophin-releasing factor in mice. Regul Pept 28:137-151. (Pubitemid 20137984)
36. Smith PA, Selley DE, Sim-Selley LJ, and Welch SP (2007) Low dose combination of morphine and delta9-tetrahydrocannabinol circumvents antinociceptive tolerance and apparent desensitization of receptors. Eur J Pharmacol 571:129-137. (Pubitemid 47379686)
37. Stevenson GW, Folk JE, Linsenmayer DC, Rice KC, and Negus SS (2003) Opioid interactions in rhesus monkeys: effects of delta + mu and delta + kappa agonists on schedule-controlled responding and thermal nociception. J Pharmacol Exp Ther 307:1054-1064. (Pubitemid 37494225)
38. Su YF, McNutt RW, and Chang KJ (1998) Delta-opioid ligands reverse alfentanil-induced respiratory depression but not antinociception. J Pharmacol Exp Ther 287:815-823. (Pubitemid 29131587)
39. Sutters KA, Miaskowski C, Taiwo YO, and Levine JD (1990) Analgesic synergy and improved motor function produced by combination of mu-delta- and mu-kappaopioids. Brain Res 530:290-294. (Pubitemid 20340709)
40. Zarrindast MR, Ramezani-Tehrani B, and Ghadimi M (2002) Effects of adrenoceptor agonists and antagonists on morphine-induced Straub tail in mice. Pharmacol Biochem Behav 72:203-207. (Pubitemid 34251328)